In AbbVie Inc.'s successful Phase 3 trial of Rinvoq, 26% of patients receiving a placebo plus topical corticosteroids met a skin-clearance benchmark, compared with two-thirds to three-quarters of patients receiving Rinvoq plus topical corticosteroids. "AbbVie Skin Treatment Successful in Phase 3 Trial" at 8:59 a.m. ET incorrectly said that 11% of the placebo patients met that skin-clearance benchmark.

 

(END) Dow Jones Newswires

July 28, 2020 18:43 ET (22:43 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more AbbVie Charts.